← Back to Search

Genomic Test

Screening Test for Detecting Ovarian and Endometrial Cancer (FemGene Trial)

N/A
Recruiting
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capacity to understand study and provide informed consent
- Capacity to understand study and provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

FemGene Trial Summary

This trial is testing a new method to screen for ovarian and endometrial cancer. The test is able to discriminate these cancers from benign disease with a high accuracy.

Who is the study for?
The DOvEEgene Phase III Trial is for peri- and postmenopausal women who can understand the study and consent to participate. Women who've had a hysterectomy, are pregnant or nursing, undergoing fertility treatments, or have a recent history of uterine perforation cannot join.Check my eligibility
What is being tested?
This trial tests the DOvEEgene test, a genomic uterine pap smear designed to detect early-stage ovarian and endometrial cancers in asymptomatic women by identifying specific cancer-related mutations with high accuracy.See study design
What are the potential side effects?
Since this is a diagnostic test rather than a treatment intervention, typical medication side effects are not applicable. However, there may be minimal risks associated with collecting the uterine pap smear sample.

FemGene Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand the study and can give my consent.
Select...
I understand the study and can give my consent.

FemGene Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Early diagnosis of ovarian and endometrial cancers
Secondary outcome measures
Evaluate costs of unnecessary intervention
Evaluate effects on quality of life from study participation
Evaluate women's experience related to study procedures
+1 more

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
443 Previous Clinical Trials
155,898 Total Patients Enrolled
McGill UniversityLead Sponsor
394 Previous Clinical Trials
994,781 Total Patients Enrolled
Genome CanadaOTHER
14 Previous Clinical Trials
23,970 Total Patients Enrolled

Media Library

DOvEEgene (Genomic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04891029 — N/A
Diagnosing Diseases Research Study Groups:
Diagnosing Diseases Clinical Trial 2023: DOvEEgene Highlights & Side Effects. Trial Name: NCT04891029 — N/A
DOvEEgene (Genomic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04891029 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment actively seeking participants?

"Affirmative. The information on clinicaltrials.gov states that this research is currently recruiting patients - it was introduced to the website on May 10th 2021 and has been updated most recently on August 23rd 2022. 3600 individuals need to be enrolled at 2 different medical sites in order for the study to progress."

Answered by AI

Could you provide an estimate of the total individuals participating in this investigation?

"Confirmed. According to the clinicaltrials.gov page, this clinical trial is in a recruiting phase and was initially posted on May 10th 2021 before being updated most recently on August 23rd 2022. The study requires 3600 patients from 2 sites for completion."

Answered by AI

Who is eligible to join this research program?

"For this medical trial, the target population are patients aged between 45 and 70 years old suffering from certain diseases. Approximately 3600 individuals need to be admitted for study participation."

Answered by AI

Is the target demographic for this research study seniors?

"The participants of this research must be aged between 45 and 70. There are 247 studies focusing on younger than 18 year-olds, while 629 focus on those over the age of 65."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Me and my partner are actively trying to conceive for almost 3 years now. We did not try any fertility treatment yet.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers
Dr. Lucy Gilbert 2021. "Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04891029.
All > Hereditary Angioedema
~1223 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top